PARP inhibitors in metastatic prostate cancer in non-castrated patients
Sessions
NEXT SESSIONSessions
Specialties
View
GENITOURINARY CANCER
PARP inhibitors in metastatic prostate cancer in non-castrated patients
Localized Bladder Cancer: Perioperative Treatment in Patients Who Are Not Eligible for Cisplatin
TKI After I0 in Renal Cell Carcinoma: FlIR Study—Lenvatinib and Everolimus vs. Cabozantinib
Pembrolizumab and Axitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma
NIAGARA Study: Perioperative Chemotherapy and Immunotherapy for Localized Bladder Cancer.
Belzutifan in Metastatic Renal Cell Carcinoma
Individualized Treatment of Metastatic Renal Cell Carcinoma
Update on Enfortumab Vedotin and Pembrolizumab in Metastatic Urothelial Cancer
ARANOTE ADT Darolutamide in Hormone-Sensitive Metastatic Prostate Cancer.
Update on Treatment with 177Lu-PSMA-617 in CPRC
Improved Survival with Adjuvant Therapy for Kidney Cancer
Metastatic hormone-sensitive prostate cancer. Which patients benefit from docetaxel?
First-Line Cisplatin-Free Chemotherapy and Immunotherapy for Metastatic Urothelial Carcinoma: A Paradigm Shift?
First-line combination of chemotherapy and immunotherapy in metastatic urothelial carcinoma
Treatment of metastatic urothelial carcinoma following chemotherapy and immunotherapy.
First-line triple therapy in patients with metastatic hormone-sensitive prostate cancer.
Adjuvant immunotherapy for invasive urothelial carcinoma.
Triple therapy for CaPHSM1.
Maintenance therapy with avelumab in metastatic urothelial carcinoma.
Adjuvant Treatment for Renal Cell Carcinoma.
Local radiation therapy for low-volume, hormone-sensitive metastatic prostate cancer.
Bladder-sparing treatment in muscle-invasive urothelial carcinoma.
Erdafitinib in metastatic urothelial carcinoma
Treatment of biochemical relapse.
LUNG CANCER
Perioperative Management in the Early Stages of Lung Cancer
Combination of targeted therapies in advanced non-small-cell lung cancer with an EGFR mutation
Perioperative Immunotherapy for Non-Small-Cell Lung Cancer
GYNECOLOGICAL CANCER
Dostarlimab as first-line therapy for advanced endometrial carcinoma
Niraparib as maintenance therapy following first-line treatment for advanced ovarian cancer
BREAST CANCER
Trastuzumab-Deruxtecan and Pertuzumab as First-Line Treatment for HER2-Positive Metastatic Breast Cancer
Maintenance Therapy with Palbociclib in RRHH+ and HER2+ Metastatic Breast Cancer
Trastuzumab Deruxtecan in HER2-low and ultra-low metastatic breast cancer
SPECIAL EPISODES
4th Anniversary - Analysis and Hospital Pharmacy Club Meeting
Introduction to Pharmacoeconomics
SEOM-SOGUG Clinical Guideline for Urothelial Cancer (2025)